The use of fetal fibronectin (fFN) testing can help reduce unnecessary admissions and hospitalizations and help direct care and resources to patients who need it most.
The Rapid fFN test is FDA approved for use in symptomatic patients between 240 and 346 weeks gestation and for asymptomatic patients between 220 and 306 weeks gestation.
The Rapid fFN test is one of several tools that help providers determine the best course of action for patients with symptoms of preterm labor. Benefits of fFN testing include increased efficiencies, without compromising clinical outcomes.
Kuwait
